Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)

被引:1247
作者
Adler, AI
Stevens, RJ
Manley, SE
Bilous, RW
Cull, CA
Holman, RR
机构
[1] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Diabet Trials Unit, Oxford, England
[2] S Cleveland Hosp, Middlesbrough, Cleveland, England
基金
美国国家卫生研究院; 英国医学研究理事会;
关键词
type; 2; diabetes; microalbuminuria; macroalbuminuria; insulin; plasma creatinine; nephropathy; end-stage renal disease;
D O I
10.1046/j.1523-1755.2003.00712.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. The progression of nephropathy from diagnosis of type 2 diabetes has not been well described from a single population. This study sought to describe the development and progression through the stages of microalbuminuria, macroalbuminuria, persistently elevated plasma creatinine or renal replacement therapy (RRT), and death. Methods. Using observed and modeled data from 5097 subjects in the UK Prospective Diabetes Study, we measured the annual probability of transition from stage to stage (incidence), prevalence, cumulative incidence, ten-year survival, median duration per stage, and risk of death from all-causes or cardiovascular disease. Results. From diagnosis of diabetes, progression to microalbuminuria occurred at 2.0% per year, from microalbuminuria to macroalbuminuria at 2.8% per year, and from macroalbuminuria to elevated plasma creatinine (greater than or equal to175 mumol/L) or renal replacement therapy at 2.3% per year. Ten years following diagnosis of diabetes, the prevalence of microalbuminuria was 24.9%, of macroalbuminuria was 5.3%, and of elevated plasma creatinine or RRT was 0.8%. Patients with elevated plasma creatinine or RRT had an annual death rate of 19.2% (95% confidence interval, CI, 14.0 to 24.4%). There was a trend for increasing risk of cardiovascular death with increasing nephropathy (P < 0.0001), with an annual rate of 0.7% for subjects in the stage of no nephropathy, 2.0% for those with microalbuminuria, 3.5% for those with macroalbuminuria, and 12.1% with elevated plasma creatinine or RRT. Individuals with macroalbuminuria were more likely to die in any year than to develop renal failure. Conclusions. The proportion of patients with type 2 diabetes who develop microalbuminuria is substantial with one quarter affected by 10 years from diagnosis. Relatively fewer patients develop macroalbuminuria, but in those who do, the death rate exceeds the rate of progression to worse nephropathy.
引用
收藏
页码:225 / 232
页数:8
相关论文
共 58 条
  • [1] American Diabetes Association, 2001, DIABETES CARE S1, V24, pS69
  • [2] [Anonymous], 2002, Coronary heart disease statistics: heart failure supplement
  • [3] ANSELL D, 1999, UK RENAL REGISTRY
  • [4] Premature cardiovascular disease in chronic renal failure
    Baigent, C
    Burbury, K
    Wheeler, D
    [J]. LANCET, 2000, 356 (9224) : 147 - 152
  • [5] EPIDEMIOLOGY OF PERSISTENT PROTEINURIA IN TYPE-II DIABETES-MELLITUS - POPULATION-BASED STUDY IN ROCHESTER, MINNESOTA
    BALLARD, DJ
    HUMPHREY, LL
    MELTON, LJ
    FROHNERT, PP
    CHU, CP
    OFALLON, WM
    PALUMBO, PJ
    [J]. DIABETES, 1988, 37 (04) : 405 - 412
  • [6] Brancati F L, 1995, Curr Opin Nephrol Hypertens, V4, P223, DOI 10.1097/00041552-199505000-00004
  • [7] Risk of end-stage renal disease in diabetes mellitus - A prospective cohort study of men screened for MRFIT
    Brancati, FL
    Whelton, PK
    Randall, BL
    Neaton, JD
    Stamler, J
    Klag, MJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (23): : 2069 - 2074
  • [8] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [9] BREYER J, 1998, PRIMER KIDNEY DIS, P215
  • [10] Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes
    Caro, JJ
    Klittich, WS
    Raggio, G
    Kavanagh, PL
    O'Brien, JA
    Shomphe, LA
    Flegel, KM
    Copley-Merriman, C
    Sigler, C
    [J]. CLINICAL THERAPEUTICS, 2000, 22 (01) : 116 - 127